5-Amino-1MQ

Overview

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule — a methylquinolinium salt — developed as a selective, membrane-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is not a peptide, even though it is frequently marketed and discussed alongside peptides in the research-chemical and "metabolic optimization" community. It is included on this wiki because it is commonly combined with, and compared to, peptides used for weight management — not because it shares their chemistry.

The rationale for studying it is metabolic: NNMT methylates nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (MNA) and consuming SAM. NNMT is overexpressed in the white adipose tissue of obese and diabetic subjects, which has made it a proposed target for obesity and type 2 diabetes. By inhibiting NNMT, 5-Amino-1MQ is proposed to preserve intracellular SAM and NAD+ pools and to suppress adipocyte lipogenesis, thereby favoring fat oxidation and energy expenditure [In vitro] / [Animal].

Almost everything known about 5-Amino-1MQ comes from cell-culture and mouse experiments, led by a single 2018 preclinical study. Descriptions of fat loss and metabolic benefit should be read as research hypotheses supported by animal and in-vitro data, not as established human effects.

Chemistry and structure

5-Amino-1MQ is a quinolinium salt: a quinoline ring bearing a methyl group on the ring nitrogen (making it a cationic quaternary/aromatic quinolinium) and an amino group at the 5-position. As a cation it is supplied as a salt with a counter-ion (databases show both chloride and iodide forms), which is why reported molecular weights differ depending on the salt.

Mechanism of action

The proposed mechanisms come almost entirely from in-vitro and mouse experiments:

• NNMT enzyme inhibition. 5-Amino-1MQ is a selective, membrane-permeable small-molecule inhibitor of NNMT enzymatic activity. NNMT catalyzes the SAM-dependent methylation of nicotinamide to 1-methylnicotinamide (MNA); inhibition reduces MNA and is proposed to preserve intracellular SAM and NAD+ pools [In vitro] / [Animal].
• Suppression of adipocyte lipogenesis. In cultured adipocytes and in diet-induced obese mice, the compound was reported to suppress fat synthesis and reduce adipocyte size and white adipose mass, an effect linked to restored NAD+/SAM and cellular energy metabolism [In vitro] / [Animal].
• Whole-body energy balance (rodent). In mice, systemic dosing was associated with reduced body weight and plasma cholesterol without a reduction in food intake, i.e. weight loss that did not depend on appetite suppression (Neelakantan et al., 2018) [Animal].
• Human efficacy — not demonstrated. No human trials have tested any of these mechanisms in people; all human-relevant claims are extrapolation from rodent and cell data [Hypothesis].

These metabolic and NAD+-linked mechanisms place 5-Amino-1MQ conceptually near molecules studied for NAD+ and mitochondrial biology, such as NAD+ and the mitochondrial-derived peptide MOTS-c — though those are different classes with their own separately limited evidence.

Research and evidence

The evidence base is weighted almost entirely toward cell and animal work, led by a single 2018 preclinical study, with no human therapeutic data.

Obesity reversal — mouse and cell evidence

In the lead study, systemic NNMT inhibition reversed high-fat-diet-induced obesity in mice: treated diet-induced obese C57BL/6 mice (reported at ~20 mg/kg, three times daily) showed reduced body weight, white adipose mass, adipocyte size and plasma total cholesterol, without a change in food intake and without overt adverse effects (Neelakantan et al., Biochemical Pharmacology 2018) [Animal]. In parallel cell-culture work, the compound lowered intracellular MNA, raised NAD+, and suppressed lipogenesis in adipocytes [In vitro]. Additional rodent work reported that a reduced-calorie diet combined with NNMT inhibition altered the gut microbiome in obese mice (Scientific Reports 2021) [Animal].

Human evidence

There is none. No published human clinical trial, no human pharmacokinetic or bioavailability data, and no placebo-controlled efficacy study exists for 5-Amino-1MQ for weight loss or any other indication. Multiple review and vendor sources concur that no human trials have been published. Any statement that 5-Amino-1MQ produces fat loss in people is an extrapolation from mouse and cell-culture results [Hypothesis], and the 20 mg/kg three-times-daily mouse regimen does not translate directly into a human dose.

Status and regulation

• Drug approval. 5-Amino-1MQ is not approved by the FDA, EMA, or any other regulator, for any indication. No marketing authorization anywhere was found in sources. It is sold only as a research reagent / unapproved investigational compound.
• Supplement status. It is a synthetic small molecule and not a lawfully marketed dietary supplement; material is typically labeled "for research use only."
• Patent context. The compound class appears in patents for quinoline-derived small-molecule NNMT inhibitors (e.g. US Patent 12071409), which confirms its classification as a small-molecule NNMT inhibitor — but a patent is not a regulatory approval.
• Sport / anti-doping. WADA prohibited status is not established in the sources reviewed — no class code was found. Do not assume it is either prohibited or permitted; athletes should verify current status directly with WADA/USADA.

Safety

Reliable human safety information for 5-Amino-1MQ is absent.

• Human safety is unknown. With no controlled human trials, there is no human safety, tolerability, or pharmacokinetic dataset, and long-term effects, toxicology, and carcinogenicity are uncharacterized in any species beyond the short obesity studies.
• Animal data do not establish human safety. The 2018 study reported no overt adverse effects in mice, but that cannot be assumed to translate to people.
• Metabolic activity warrants caution. A compound that alters NAD+/SAM metabolism and lipid handling could, in principle, interact with metabolism, medications, or existing conditions in ways that have not been studied in humans.
• Unregulated product quality. Material sold as 5-Amino-1MQ is an unregulated research chemical. Identity, purity, salt form, dosing accuracy, and contamination are real concerns independent of the molecule itself.

Legal status

The legal status of 5-Amino-1MQ has not been assessed in this article and varies by jurisdiction. It is not an approved medicine anywhere found in sources and is sold only as an unapproved research reagent; it should not be described as "legal" or "safe for human use." Anyone considering it must check the laws of their own country. WADA status is separate and not established in the sources reviewed.

How it compares

5-Amino-1MQ is often discussed next to peptides and NAD+-related molecules in the metabolic and weight-management space, but it is a different class of compound.

Bottom line: Among these, only retatrutide has direct human efficacy data for weight loss. 5-Amino-1MQ rests on a single preclinical study plus in-vitro work and has no human data at all; sharing a "metabolic" category with an incretin peptide does not imply comparable evidence.

Common misconceptions

• "5-Amino-1MQ is a peptide." It is not. It is a synthetic small-molecule quinolinium salt that inhibits the NNMT enzyme; it is only discussed alongside peptides because the community combines them.
• "It's a proven fat-loss compound." The efficacy evidence is mouse and cell culture only. No human trial has shown it causes fat loss in people.
• "The mouse dose tells you the human dose." The ~20 mg/kg three-times-daily mouse regimen does not translate directly to humans, and no human PK data exist to calibrate a dose.
• "It's FDA-approved or a legal supplement." It is neither an approved drug nor a lawfully marketed dietary supplement — it is an unapproved research reagent.
• "NNMT is a validated human weight-loss target." NNMT is a proposed target supported by target-rationale reviews and animal data, not by completed human therapeutic trials of NNMT inhibitors.